Navigation Links
Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
Date:8/19/2010

SAN FRANCISCO, Aug. 19 /PRNewswire/ -- Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer, today announced the closing of a fully subscribed private placement financing with aggregate gross proceeds of approximately $8.6 million.

Proceeds from this transaction will be used to advance the Company's oncology product platform, led by JX-594, a novel oncolytic agent that has demonstrated promising antitumor activity in Phase 1 and Phase 2 clinical trials.

"This important round of financing provides us with funds necessary to continue to advance our pipeline of promising oncology products through clinical development and to achieve a number of corporate and clinical milestones.  This includes the completion of the ongoing JX-594 Phase 2 clinical trials currently underway for patients with liver cancer and colorectal cancer," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "We appreciate the support from many of our existing stockholders as well as a number of new important investors who chose to participate in this successful financing."

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib.  Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types.  JX-594 and other product candidates under development are designed to attack cancer tumors through three diver
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
2. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
3. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
6. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
7. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
8. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
9. DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management
10. Resverlogix Completes Dosing for ASSERT Trial
11. Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Vieillard as Sales & Marketing Director. , With more than 25 years ... responsible for reinforcing Tronics’ business development activities worldwide. He brings to the company ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... BEIJING, China, Oct. 2 /PRNewswire-Asia-FirstCall/ -- Yongye International,Inc. (Nasdaq: ... manufacturer,developer and distributor of Shengmingsu brand plant and animal ... announced its 2010-,2012 strategic plan. , ... and thus far in,2009, Yongye expects to achieve at ...
... ... with the addition of Situational Leadership V™ series to its portfolio. , ... San Francisco, Calif. (PRWEB) ... Situational Leadership V (SLV) series specifically for biotech and specialty pharma companies. The new ...
... LAFAYETTE, Ind. - Researchers have overcome a major obstacle ... to create a new class of electronics that would ... Carbon nanotubes, which were discovered in the early 1990s, ... as well as ultra-thin "nanowires" for electronic circuits. The ...
Cached Biology Technology:Yongye International Announces 2010-2012 Strategic Plan 2Yongye International Announces 2010-2012 Strategic Plan 3Yongye International Announces 2010-2012 Strategic Plan 4Yongye International Announces 2010-2012 Strategic Plan 5Perceptum Group Announces New Situational Leadership V Series 2Better control of carbon nanotube 'growth' promising for future electronics 2Better control of carbon nanotube 'growth' promising for future electronics 3
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market Intelligence,s ... The Convergence of Commerce and Privacy" forecasts that ... biometric apps will be downloaded to smart mobile ... mobile biometrics market is projected to generate more ... during the seven-year forecast period.    ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... be delivering a one-two punch to newts, according to ... disease outbreaks in amphibians. , The findings could also ... such as malaria, chagas disease and sleeping sickness. All ... that spreads disease from one animal to another. ...
... developed mutualistic relationships with the plant viruses it transmits ... on virus-infected plants than on healthy plants, whereas its ... the new research carried out at Zhejiang University and ... ago in 1986 in the USA, Florida experienced outbreaks ...
... mysteries of the brain is how it avoids ending up ... exceptional occasions, when it can lead to epileptic fits. Scientists ... how the brain keeps its neuronal activity in check. ... nerve cells linked together by around ten billion contact junctions ...
Cached Biology News:Leeches ferry infection among newts 2Whiteflies and plant viruses can help each other to speed up biological invasion 2Rare cell prevents rampant brain activity 2
... Anti-Natural Killer Cell Receptor-P1, ... Immunogen: Hybridoma produced ... from BALB/c mice immunized (BALB/c ... (LAK) cells and mouse myeloma ...
... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: